Memorial Sloan Kettering Cancer Center
Pharmaceutical payments, increased prescribing go hand in hand
Financial payments from pharmaceutical companies were “consistently associated with increased prescribing” across a wide range of physician specialties, drug classes and prescribing decisions, according to the authors of a recent review.
Inaugural class of FDA-AACR oncology educational fellows announced
American Association for Cancer Research announced the 2020-2021 class of FDA-AACR oncology educational fellows.
Letetresgene autoleucel safe, active in advanced synovial sarcoma
Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.
Letetresgene autoleucel safe, active in advanced synovial sarcoma
Letetresgene autoleucel demonstrated clinical activity among patients with advanced synovial sarcoma, according to final phase 1 study results presented at the virtual Society for Immunotherapy of Cancer Annual Meeting.
Genomic alterations in prostate cancer appear to vary according to race
Tumor genomic alterations appeared to differ among Black, white and Asian men with prostate cancer, according to results of a study published in The New England Journal of Medicine.
Critically ill patients with cancer, COVID-19 at high risk for severe disease, mortality
New data presented at the virtual CHEST Annual Meeting add to the growing body of evidence of the increased risk for mortality and severe disease in patients with cancer and COVID-19.
Many patients with colorectal liver metastases not referred for resection, despite benefit
Resection of colorectal liver metastases, often performed in conjunction with chemotherapy, can substantially extend survival — a fact that has been acknowledged for about 20 years.
One in three patients reports gaps in knowledge of cancer treatment adverse effects
When meeting with an oncologist to discuss treatment plans, newly diagnosed patients with cancer must process significant amounts of new information.
Nivolumab may be ‘new standard’ in esophageal, gastroesophageal junction cancers
Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.